A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome
- 19 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (3), 1364-1375
- https://doi.org/10.1093/rheumatology/keaa410
Abstract
This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren’s syndrome (PSS). Adults with PSS were randomized 1:1 to seletalisib 45 mg/day or placebo, in addition to current PSS therapy. Primary end points were safety and tolerability and change from baseline in EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) score at week 12. Secondary end points included change from baseline at week 12 in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) score and histological features in salivary gland biopsies. Twenty-seven patients were randomized (seletalisib n = 13, placebo n = 14); 20 completed the study. Enrolment challenges led to early study termination with loss of statistical power (36% vs 80% planned). Nonetheless, a trend for improvement in ESSDAI and ESSPRI [difference vs placebo: –2.59 (95% CI: –7.30, 2.11; P=0.266) and –1.55 (95% CI: –3.39, 0.28), respectively] was observed at week 12. No significant changes were seen in saliva and tear flow. Serious adverse events (AEs) were reported in 3/13 of patients receiving seletalisib vs 1/14 for placebo and 5/13 vs 1/14 discontinued due to AEs, respectively. Serum IgM and IgG concentrations decreased in the seletalisib group vs placebo. Seletalisib demonstrated efficacy in reducing size and organisation of salivary gland inflammatory foci and in target engagement, thus reducing PI3K-mTOR signalling compared with placebo. Despite enrolment challenges, seletalisib demonstrated a trend towards clinical improvement in patients with PSS. Histological analyses demonstrated encouraging effects of seletalisib on salivary gland inflammation and organisation. https://clinicaltrials.gov, NCT02610543.Keywords
Funding Information
- UCB Pharma
This publication has 21 references indexed in Scilit:
- Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's SyndromeJoint Bone Spine, 2017
- First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseasesEuropean Journal of Clinical Pharmacology, 2017
- Recent advances in primary Sjogren's syndromeF1000Research, 2016
- Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent ColitisPublished by The American Association of Immunologists ,2014
- Treatment of Primary Sjögren Syndrome With RituximabAnnals of Internal Medicine, 2014
- Signaling by the Phosphoinositide 3-Kinase Family in Immune CellsAnnual Review of Immunology, 2013
- Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignanciesFrontiers in Immunology, 2012
- Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid‐like structures in Sjögren's syndromeArthritis & Rheumatism, 2005
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- p110δ, a novel phosphoinositide 3-kinase in leukocytesProceedings of the National Academy of Sciences, 1997